Treatment of Acquired Dermal Macular Hyperpigmentation With Oral Isotretinoin: A Multi‐Institutional Retrospective Study of 121 Cases
Pigment Cell & Melanoma Research · 2025
DOI: 10.1111/pcmr.70052 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Pigment Cell & Melanoma Research, 2025. Verfasst von Zhongyi Xu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, People's Republic of China. Hauptthemen laut MEDLINE: Isotretinoin, Hyperpigmentation, Dermatologic Agents. Die Arbeit nennt 25 Literaturangaben.
Abstract (Originalsprache)
The term acquired dermal macular hyperpigmentation (ADMH) was introduced to unify Riehl's melanosis (RM), lichen planus pigmentosus (LPP), and related entities. These are cosmetically distressing pigmentary disorders that pose therapeutic challenges. To investigate the efficacy and safety of oral isotretinoin in treating ADMH, we conducted a muticenter retrospective study of patients with ADMH treated with oral isotretinoin between 2014 and 2024. Patients from Australia, China, Europe, India, Middle East, North America, and North Africa were included. Patients lost to follow‐up before two visits were excluded. The response was graded by a 5‐point Investigator's Global Assessment (IGA) scale. A total of 121 patients were included. Most patients (64.5%) were treated with a dose of 20 mg/d for an average of 8 months. Oral isotretinoin improved the severity of pigmentation in all RM and 85 (90.4%) LPP patients, with 17 (63.0%) RM and 31 (33.0%) LPP patients achieving marked improvement. RM patients responded better than LPP patients ( p = 0.005). Patients with localized lesions ( p = 0.0012), disease duration of less than 5 years ( p = 0.046 for RM, p = 0.0272 for LPP), Fitzpatrick skin phototypes III‐VI ( p = 0.0081), or longer duration of treatment ( p = 0.0178) responded better. Oral isotretinoin appears to be a promising treatment modality for ADMH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, People's Republic of China.
- Department of Dermatology, Venereology and Leprology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
- Department of Dermatology, The Royal Children's Hospital Melbourne, Melbourne, Victoria, Australia.
- Department of Paediatrics, The University of Melbourne, Parkville, Victoria, Australia.
- Chroma Dermatology, Melbourne, Victoria, Australia.
- Department of Medicine, Faculty of Medicine, Kuwait University, Jabriya, Kuwait.
ORCID-Profile: Zhongyi Xu, Yuecen Ding, Chengfeng Zhang, Davinder Parsad, Michelle Rodrigues, Nawaf Almutairi, Jharna Amin, Leihong Xiang, Thierry Passeron
Zitieren
APA
Xu, Z., Ding, Y., Zhang, C., Parsad, D., Rodrigues, M., Kumaran, M. S., Almutairi, N., Hamzavi, I., Amin, J., Ghorbel, H. H., Xiang, L., & Passeron, T. (2025). Treatment of Acquired Dermal Macular Hyperpigmentation With Oral Isotretinoin: A Multi‐Institutional Retrospective Study of 121 Cases. Pigment Cell & Melanoma Research. https://doi.org/10.1111/pcmr.70052
Vancouver
Xu Z, Ding Y, Zhang C, Parsad D, Rodrigues M, Kumaran MS, et al. Treatment of Acquired Dermal Macular Hyperpigmentation With Oral Isotretinoin: A Multi‐Institutional Retrospective Study of 121 Cases. Pigment Cell & Melanoma Research. 2025. doi:10.1111/pcmr.70052
BibTeX
@article{Xu2025,
author = {Xu, Zhongyi and Ding, Yuecen and Zhang, Chengfeng and Parsad, Davinder and Rodrigues, Michelle and Kumaran, Muthu Sendhil and Almutairi, Nawaf and Hamzavi, Iltefat and Amin, Jharna and Ghorbel, Houda Hammami and Xiang, Leihong and Passeron, Thierry},
title = {Treatment of Acquired Dermal Macular Hyperpigmentation With Oral Isotretinoin: A Multi‐Institutional Retrospective Study of 121 Cases},
journal = {Pigment Cell & Melanoma Research},
year = {2025},
doi = {10.1111/pcmr.70052}
}
EUVIMED